ArticleClinicoEconomics and outcomes research : CEOR2025

A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy.

Stefano Luminari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.